A phase II exploratory study of durvalumab (MEDI4736) in HIV-1 patients with advanced solid tumors
M. Gonzalez-Cao, J. Martinez- Picado, M. Provencio, B. Clotet, O. Juan, J. Dalmau, T. Moran, A. Meyerhans, J. de Castro, J. Blanco, R. Bernabe, N. Karachaliou, J. Garcia-Corbacho, R. Blanco, C. Brander, J. Carrillo, MA. Molina, R. Rosell
A randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial
S. Postel-Vinay, D. Planchard, A.L. Ortega Granados, A. Gazzah, M.A. Sala Gonzalez,
M. Majem, C.J. Camps, A. Abou-Lauvergne, J-P. Pignon, J. Cadranel, J. Bennouna,
F. Barlesi, M.R. Garcia Campelo, S. Viteri, B. Besse, J. Coves Sarto, B. Massuti
Sureda, J-C. Soria, R. Rosell
Intracranial Efficacy of Brigatinib (BRG) in Patients (Pts) With Crizotinib (CRZ)-Refractory Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer (NSCLC) and Baseline CNS Metastases
Sai-Hong Ignatius Ou, Marcello Tiseo, D Ross Camidge, Myung-Ju Ahn, Rudolf M Huber, Maximilian J Hochmair, Sang-We Kim, Howard L West, Karen L Reckamp, Julian R Molina, Geoffrey Liu, Angelo Delmonte, Santiago Viteri, Alessandra Bearz, Yvonne Summers, William Reichmann, David Kerstein, Scott N Gettinger, Dong-Wan Kim
ONCOS-102 and pemetrexed/cisplatin in patients with unresectable
malignant pleural mesothelioma
S. Ponce Aix, S. Viteri, J. Bosch-Borrera, L. Kuryk, T. Hakonen, S. Vetrhus,
M. Jaderberg, L. Paz-Ares
Brigatinib in Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer (NSCLC): Long-term Efficacy and Safety Results From a Phase 1/2 Trial
Lyudmila A Bazhenova, Scott N Gettinger, Corey J Langer, Ravi Salgia, Kathryn A Gold, Rafael Rosell, Alice T Shaw, Glen J Weiss, Jeff Haney, Victor M Rivera, David Kerstein, D Ross Camidge
Prospective comparison of liquid biopsy to standard of care tissue testing in metastatic, non-squamous, non-small cell lung cancer (NSCLC) patients (pts)
R. Palmero, A. Taus, M. Majem Tarruella, S. Viteri, E. Carcereny Costa, J. Garde,
E. Felip Font, C. Cassidy, D. Dix, N. Karachaliou, R. Rosell
Multicenter, nonrandomized, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy: results in malignant pleural mesothelioma (MPM)
J.M. Trigo Perez, E. van Brummelen, E. Levchenko, M. Domine Gomez, D.A. Fennell, H.L. Kindler, S. Viteri, S. Gadgeel, P. Garrido Lopez, V. Kostorov, D. Morgensztern, S. Orlov, P.K. Paik, J.F. Vansteenkiste, X. Wang, A. Sharabidze, M.P. Deyoung, K.P. Baker, L. Yan, I. Mitrica
Clinical value of cfDNA and CTCs in EGFR mutations detected in advanced NSCLC
S. Calabuig Farinas, E. Jantus-Lewintre, A. Fernandez, C. Mayo de las Casas,
A. Blasco, C. Aguilar, N. Jordana, A. Balada, M. Garzon Ibanez, F. Zhang, N. Dong, M.A. Molina, R. Rosell, C. Camps Herrero
